e-Drug3D

1622

cas 1051375-16-6

CLASS

ANTIINFECTIVES
HIV-1 ANTIVIRAL AGENT
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INTEGRASE STRAND TRANSFER INHIBITOR
P-GLYCOPROTEIN SUBSTRATE

ROUTE (list)

ORAL

PK parameters

VD 17.4 LITER
Cl 1 LITER / HOUR
PPB 98.9 PERCENT
t1/2 14 HOUR

TARGET HIV-1 INTEGRASE

PDB
3S3O (CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) N224H MUTANT INTASOME IN COMPLEX WITH MAGNESIUM AND DOLUTEGRAVIR (S, GSK1349572))

Ligand code = DLU (link to the list of PDB complexes)

Download experimental 3D coordinates of DLU with added hydrogens

MW 419.38
NB_atoms 30
XLogP 1.35
PSA 88.768
NB_HD 2
NB_HA 8
fsp3 0.35
Lipinski(0=no;1=yes) 1

FDA
NDA 204790 (label) INN (DOLUTEGRAVIR SODIUM) TIVICAY (VIIV HLTHCARE) APPROVAL= AP YEAR= 2013
NDA 205551 (label) INN (ABACAVIR SULFATE ; DOLUTEGRAVIR SODIUM ; LAMIVUDINE) TRIUMEQ (VIIV HLTHCARE) APPROVAL= AP YEAR= 2014
NDA 208355 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (AUROBINDO PHARMA LTD) APPROVAL= TA YEAR= 2016
NDA 209670 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR DISOPROXIL FUMARATE) DOLUTEGRAVIR, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE (MYLAN PHARMS INC) APPROVAL= TA YEAR= 2017
NDA 210192 (label) INN (DOLUTEGRAVIR SODIUM ; RILPIVIRINE HYDROCHLORIDE) JULUCA (VIIV HLTHCARE) APPROVAL= AP YEAR= 2017
NDA 209602 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (MYLAN LABS LTD) APPROVAL= TA YEAR= 2018
NDA 209658 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (CIPLA LTD) APPROVAL= TA YEAR= 2018
NDA 210787 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR DISOPROXIL FUMARATE) DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE (LAURUS LABS LTD) APPROVAL= TA YEAR= 2019
NDA 211994 (label) INN (DOLUTEGRAVIR SODIUM ; LAMIVUDINE) DOVATO (VIIV HLTHCARE) APPROVAL= AP YEAR= 2019
NDA 210963 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (LAURUS LABS LTD) APPROVAL= TA YEAR= 2019
NDA 212179 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (MICRO LABS LTD) APPROVAL= TA YEAR= 2019
NDA 210796 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR DISOPROXIL FUMARATE) DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE (MACLEODS PHARMS LTD) APPROVAL= TA YEAR= 2019
NDA 213983 (label) INN (DOLUTEGRAVIR SODIUM) TIVICAY PD (VIIV HLTHCARE) APPROVAL= AP YEAR= 2020
NDA 213556 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR DISOPROXIL FUMARATE) DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (SHANGHAI DESANA BIO-PHARMACEUTICALS CO LTD) APPROVAL= TA YEAR= 2020
NDA 210812 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (CIPLA LTD) APPROVAL= TA YEAR= 2021
NDA 212303 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR DISOPROXIL FUMARATE) DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (LUPIN PHARMS) APPROVAL= TA YEAR= 2021
NDA 214397 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (MACLEODS PHARMS LTD) APPROVAL= TA YEAR= 2021
NDA 214566 (pdf not found) INN (DOLUTEGRAVIR SODIUM) DOLUTEGRAVIR SODIUM (MACLEODS PHARMS LTD) APPROVAL= TA YEAR= 2021
NDA 212527 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR ALAFENAMIDE) DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE (CIPLA USA INC.) APPROVAL= TA YEAR= 2022
NDA 215413 (label) INN (ABACAVIR SULFATE ; DOLUTEGRAVIR SODIUM ; LAMIVUDINE) TRIUMEQ PD (VIIV HLTHCARE) APPROVAL= AP YEAR= 2022
NDA 216223 (pdf not found) INN (ABACAVIR ; DOLUTEGRAVIR ; LAMIVUDINE) ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE (LAURUS LABS LTD) APPROVAL= TA YEAR= 2022
NDA 213120 (pdf not found) INN (DOLUTEGRAVIR ; RILPIVIRINE) DOLUTEGRAVIR; RILPIVIRINE (LUPIN LTD) APPROVAL= TA YEAR= 2023
NDA 214544 (pdf not found) INN (DOLUTEGRAVIR ; EMTRICITABINE ; TENOFOVIR ALAFENAMIDE) DOLUTEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE (LUPIN LTD) APPROVAL= TA YEAR= 2023
NDA 215319 (pdf not found) INN (DOLUTEGRAVIR) DOLUTEGRAVIR (LAURUS GENERICS INC) APPROVAL= TA YEAR= 2023
NDA 215448 (pdf not found) INN (DOLUTEGRAVIR ; EMTRICITABINE ; TENOFOVIR ALAFENAMIDE) DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE (AUROBINDO PHARMA USA) APPROVAL= TA YEAR= 2023
NDA 211868 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR DISOPROXIL FUMARATE) DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE (EMCURE PHARMS LTD) APPROVAL= TA YEAR= 2023
NDA 215187 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE ; TENOFOVIR ALAFENAMIDE) DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE (LUPIN PHARMS) APPROVAL= TA YEAR= 2023
NDA 217016 (pdf not found) INN (DOLUTEGRAVIR ; TENOFOVIR DISOPROXIL FUMARATE ; LAMIVUDINE) DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE (STRIDES PHARMA) APPROVAL= TA YEAR= 2023
NDA 217070 (pdf not found) INN (ABACAVIR ; DOLUTEGRAVIR ; LAMIVUDINE) ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE (AUROBINDO PHARMA USA) APPROVAL= TA YEAR= 2023
NDA 212181 (pdf not found) INN (ABACAVIR ; DOLUTEGRAVIR ; LAMIVUDINE) ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE (EMCURE PHARMS LTD) APPROVAL= TA YEAR= 2024
NDA 218383 (pdf not found) INN (ABACAVIR ; DOLUTEGRAVIR ; LAMIVUDINE) ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE (LUPIN LTD) APPROVAL= TA YEAR= 2024
NDA 210391 (pdf not found) INN (ABACAVIR ; DOLUTEGRAVIR ; LAMIVUDINE) ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE (CIPLA LIMITED) APPROVAL= TA YEAR= 2025
NDA 210811 (pdf not found) INN (ABACAVIR ; DOLUTEGRAVIR ; LAMIVUDINE) DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE (CIPLA LIMITED) APPROVAL= TA YEAR= 2025
NDA 219623 (pdf not found) INN (DOLUTEGRAVIR ; LAMIVUDINE) DOLUTEGRAVIR AND LAMIVUDINE (EMCURE PHARMS LTD) APPROVAL= TA YEAR= 2025